Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Tagrisso“
Suchtreffer
Begriffe & Kennungen
Tagrisso · 4.8 · In the ADAURA, FLAURA, FLAURA2, LAURA and AURA studies (TAGRISSO monotherapy; N=1956), diarrhoea was reported
Eintrag öffnenTagrisso · 4.8 · In the LAURA study, following definitive platinum-based chemoradiation therapy, radiation pneumonitis was repo
Eintrag öffnenTagrisso · 4.8 · Interstitial lung Common (4.3%)g 1.4%h Common (3.3%)i 0.7%j disease Radiation Common (4%) 0.2% 0% 0% Pneumonit
Eintrag öffnenTagrisso · 4.8 · Interstitial lung disease (ILD)
Eintrag öffnenTagrisso · 4.8 · Leukopenia Common (5%) 0.4% Very common (12.7%) 2.9%
Eintrag öffnenTagrisso · 4.8 · Low body weight
Eintrag öffnenTagrisso · 4.8 · Lymphopenia Common (1.6%) 0.3% Common (2.5%) 1.1%
Eintrag öffnenTagrisso · 4.8 · MedDRA SOC TAGRISSO with pemetrexed and TAGRISSOa and MedDRA platinum-based chemotherapyb term CIOMS descripto
Eintrag öffnenTagrisso · 4.8 · Metabolism and nutrition disorders Decreased appetite Very common (19%) 1.1% Very common (31%) 2.9%
Eintrag öffnenTagrisso · 4.8 · Neutropenia Common (6%) 0.9% Very common (24.6%) 13.4%
Eintrag öffnenTagrisso · 4.8 · Of the 1956 patients in ADAURA, FLAURA, FLAURA2, LAURA and AURA studies treated with TAGRISSO monotherapy 80 m
Eintrag öffnenTagrisso · 4.8 · Patients receiving TAGRISSO monotherapy (80 mg; N=1956) with low body weight (<50 kg) reported higher frequenc
Eintrag öffnenTagrisso · 4.8 · Patients with a medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatmen
Eintrag öffnenTagrisso · 4.8 · QTc interval prolongation
Eintrag öffnenTagrisso · 4.8 · Radiation pneumonitis
Eintrag öffnenTagrisso · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenTagrisso · 4.8 · Respiratory, thoracic and mediastinal disorders Epistaxis Common (6%) 0% Common (7%) 0.4%
Eintrag öffnenTagrisso · 4.8 · Skin and subcutaneous tissue disorders Rashm Very common (45%) 0.8% Very common (49%) 2.5% Paronychian Very co
Eintrag öffnenTagrisso · 4.8 · Stomatitisl Very common (23%) 0.4% Very common (31%) 0.4%
Eintrag öffnenTagrisso · 4.8 · Studies in EGFR mutation-positive NSCLC patients
Eintrag öffnen